NeuroOne Medical reports Q1 EPS 6c vs. (14c) last year

Reports Q1 product revenue $3.3M vs. $1M last year. Reports Q1 license revenue $3M vs. $0 last year. “This quarter marks the next step forward in expanding our commercialization efforts as we continue executing on our strategic partnership with Zimmer Biomet,” said Dave Rosa, CEO of NeuroOne. “Early patient successes reinforce the clinical value of the OneRF Ablation System, the first and only FDA-cleared device that performs both recording and RF ablation in the brain using the same device. We expect this momentum to translate into broader market adoption and a strong revenue profile which will allow us to advance our product portfolio and drive shareholder value. We remain on track to submit a 510(k) application to the FDA in the first half of calendar year 2025 for our new trigeminal nerve radiofrequency ablation system designed to treat patients with debilitating facial pain. We are also pleased that we have regained compliance with Nasdaq’s share price listing standards and are grateful to our shareholders for their patience during this time.”